Compare CGEM & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGEM | VSTM |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.7M | 723.8M |
| IPO Year | 2021 | 2012 |
| Metric | CGEM | VSTM |
|---|---|---|
| Price | $10.19 | $6.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $28.00 | $13.38 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 02-26-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,379,000.00 |
| Revenue This Year | N/A | $208.54 |
| Revenue Next Year | N/A | $251.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 33.79 |
| 52 Week Low | $5.68 | $4.01 |
| 52 Week High | $13.33 | $11.25 |
| Indicator | CGEM | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 49.47 | 29.57 |
| Support Level | $9.41 | $6.68 |
| Resistance Level | $10.70 | $8.14 |
| Average True Range (ATR) | 0.61 | 0.49 |
| MACD | -0.12 | -0.15 |
| Stochastic Oscillator | 40.66 | 6.52 |
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.